15 hours ago
European Market Gems Ion Beam Applications And 2 Companies That Might Be Priced Below Their True Worth
As European markets face challenges from geopolitical tensions and economic uncertainties, investors are increasingly focused on identifying stocks that may be undervalued amidst the broader market fluctuations. In this environment, a good stock is often characterized by strong fundamentals and potential for growth that isn't fully reflected in its current price, making it an intriguing prospect for those looking to capitalize on market inefficiencies.
Name
Current Price
Fair Value (Est)
Discount (Est)
VIGO Photonics (WSE:VGO)
PLN518.00
PLN1020.19
49.2%
TTS (Transport Trade Services) (BVB:TTS)
RON4.335
RON8.48
48.9%
Trøndelag Sparebank (OB:TRSB)
NOK114.02
NOK223.09
48.9%
Sparebank 68° Nord (OB:SB68)
NOK180.00
NOK357.67
49.7%
Qt Group Oyj (HLSE:QTCOM)
€54.60
€108.20
49.5%
Lingotes Especiales (BME:LGT)
€6.05
€11.83
48.8%
Koskisen Oyj (HLSE:KOSKI)
€8.80
€17.32
49.2%
doValue (BIT:DOV)
€2.31
€4.51
48.8%
Boreo Oyj (HLSE:BOREO)
€14.85
€29.49
49.7%
Andritz (WBAG:ANDR)
€59.30
€116.27
49%
Click here to see the full list of 177 stocks from our Undervalued European Stocks Based On Cash Flows screener.
We're going to check out a few of the best picks from our screener tool.
Overview: Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally with a market cap of €351.20 million.
Operations: The company's revenue segments include €65.88 million from Dosimetry and €436.36 million from Proton Therapy and Other Accelerators.
Estimated Discount To Fair Value: 45.3%
Ion Beam Applications is trading at €12, significantly below its estimated fair value of €21.95, indicating potential undervaluation based on cash flows. The company recently reported a turnaround to profitability with a net income of €9.25 million for 2024 and forecasts earnings growth of over 30% annually, outpacing the Belgian market's growth rate. Additionally, Ion Beam has initiated a share repurchase program and secured new contracts in Taiwan for its proton therapy systems.
Our growth report here indicates Ion Beam Applications may be poised for an improving outlook.
Delve into the full analysis health report here for a deeper understanding of Ion Beam Applications.
Overview: STIF Société anonyme manufactures and sells components for the handling of bulk products in France, with a market cap of €274.23 million.
Operations: The company generates revenue of €63.70 million from its Machinery & Industrial Equipment segment.
Estimated Discount To Fair Value: 32.2%
STIF Société anonyme is trading at €53.4, substantially below its estimated fair value of €78.79, highlighting potential undervaluation based on cash flows. The company reported a significant increase in net income to €9.7 million for 2024 from €2 million the previous year, with earnings projected to grow faster than the French market at 16% annually. Despite recent share price volatility, revenue is expected to increase by 14.7% per year, surpassing market growth rates.
Our comprehensive growth report raises the possibility that STIF Société anonyme is poised for substantial financial growth.
Get an in-depth perspective on STIF Société anonyme's balance sheet by reading our health report here.
Overview: Biotage AB (publ) offers solutions and products for drug discovery and development, analytical testing, and water and environmental testing, with a market cap of SEK11.48 billion.
Operations: Biotage generates revenue from its Healthcare Software segment, amounting to SEK1.96 billion.
Estimated Discount To Fair Value: 20.7%
Biotage AB is trading at SEK 143.4, below its estimated fair value of SEK 180.92, indicating potential undervaluation based on cash flows. Despite recent earnings decline to SEK 4 million from SEK 33 million a year ago, the company's earnings are forecast to grow significantly at over 20% annually, outpacing the Swedish market's growth rate. However, recent insider selling and share price volatility may concern some investors amidst an ongoing acquisition offer by Kohlberg Kravis Roberts & Co. L.P.
Upon reviewing our latest growth report, Biotage's projected financial performance appears quite optimistic.
Click here to discover the nuances of Biotage with our detailed financial health report.
Click this link to deep-dive into the 177 companies within our Undervalued European Stocks Based On Cash Flows screener.
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTBR:IBAB ENXTPA:ALSTI and OM:BIOT.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
